The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients
NCT03292861 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-01-14
Summary
This is a randomized, controlled, single center study to evaluate the efficacy of Thymoglobulin induction therapy in combination with Mycophenolate Mofetil, tacrolimus, and steroids in the prevention of CAV. Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.
Mechanistic assays (T-reg cells, Lym subsets, B cell subsets, IL-1b, cytokines, TGFb, IL-21 to be drawn at Pre-transplant, 3, 6, 12 months post-transplant) will also be performed.
All patients will be followed and monitored according to standard of care protocols for heart transplant recipients at our center.
Conditions
- Heart Transplantation
Interventions
- DRUG
-
Thymoglobulin
Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.
- DRUG
-
Mycophenolate Mofetil
3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
- DRUG
-
Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.
- DRUG
-
Sirolimus
Maintenance doses of sirolimus at 12 months post-transplantation
- DRUG
-
125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
Sponsors & Collaborators
-
Genzyme, a Sanofi Company
collaborator INDUSTRY -
Cedars-Sinai Medical Center
lead OTHER
Principal Investigators
-
Jon Kobashigawa, MD · Director
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-09-13
- Primary Completion
- 2026-03-31
- Completion
- 2026-03-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant
NCT03099122 ·Status: COMPLETED ·Phase: PHASE4
-
Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation
NCT00592306 ·Status: WITHDRAWN ·Phase: PHASE3
-
Antibody and Delayed Cyclosporine Versus Initial Cyclosporine Alone in Patients Receiving Kidney Transplants
NCT00007787 ·Status: COMPLETED ·Phase: NA
-
Prospective Pilot Study of Pre-Transplant Thymoglobulin Administration in Living Donor Renal Transplant Recipients
NCT00771745 ·Status: COMPLETED ·Phase: PHASE4
-
Safety Trial of Single Versus Multiple Dose Thymoglobulin Induction in Kidney Transplantation
NCT00906204 ·Status: COMPLETED ·Phase: PHASE2
-
An Open-label, Prospective, Randomized, Multi-center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients.
NCT00235300 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Thymoglobulin to Protect Kidney Function After Liver Transplant
NCT00970073 ·Status: COMPLETED ·Phase: NA
-
Single Dose Thymoglobulin for Induction in Adult Renal Allograft Recipients
NCT00235781 ·Status: TERMINATED ·Phase: NA
-
Induction Therapy Study in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
NCT00275509 ·Status: COMPLETED ·Phase: PHASE3
-
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
NCT00006178 ·Status: COMPLETED ·Phase: PHASE2
-
Thymoglobulin Induction in Kidney Transplant Recipients
NCT01239563 ·Status: UNKNOWN ·Phase: PHASE3
-
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Living Donor Renal Transplantation
NCT00681343 ·Status: COMPLETED ·Phase: PHASE4
-
A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation
NCT02544113 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
NCT01336296 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
NCT01154387 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Thymoglobulin Versus Alemtuzumab Versus Daclizumab in Living Donor Renal Transplantation
NCT01046955 ·Status: COMPLETED ·Phase: PHASE4
-
TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation
NCT03943238 ·Status: RECRUITING ·Phase: PHASE1
-
Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients
NCT00782821 ·Status: COMPLETED ·Phase: PHASE4
-
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
NCT00305396 ·Status: COMPLETED ·Phase: PHASE4
-
Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children
NCT04924491 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
NCT00076570 ·Status: COMPLETED ·Phase: PHASE2
-
Thymoglobulin Versus Campath-1H Versus Daclizumab in Adult, Primary Deceased Donor Renal Transplantation
NCT00685061 ·Status: COMPLETED ·Phase: PHASE4
-
Thymoglobulin Induction Therapy With Minimal Immunosuppression and Evaluation of Allograft Status
NCT00731874 ·Status: TERMINATED ·Phase: PHASE4
-
Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
NCT01305395 ·Status: WITHDRAWN ·Phase: NA
-
Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation
NCT01149993 ·Status: WITHDRAWN ·Phase: PHASE4